Wave Life Sciences shares are trading lower after the company announced on Tuesday WVE-004 did not show clinical benefit compared with the placebo. Mizuho cut its price target on the stock from $13 to $10.
Portfolio Pulse from Benzinga Newsdesk
Wave Life Sciences' stock is trading lower after announcing that WVE-004 showed no clinical benefit compared to the placebo. Mizuho has reduced its price target on the stock from $13 to $10.
May 24, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wave Life Sciences' WVE-004 failed to show clinical benefit, leading to a lower stock price and a reduced price target by Mizuho.
Wave Life Sciences announced that WVE-004 did not show clinical benefit compared to the placebo, which is a negative development for the company. This has led to a lower stock price and a reduced price target by Mizuho, indicating a negative short-term impact on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100